Literature DB >> 15386371

Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.

Eugenio Marcuello1, Albert Altés, Elisabeth del Rio, Angeles César, Anna Menoyo, Montserrat Baiget.   

Abstract

Thymidylate synthase (TS) is the primary target of 5-fluorouracil (5-FU). A VNTR polymorphism in the TS promoter region is associated with the efficacy of 5-FU-based chemotherapy in colorectal cancer. A common G>C SNP at the 12th nucleotide of the second repeat in the TS*3 alleles has been recently described. The combination of SNP and VNTR allows the definition of 3 TS alleles: *2, *3G and *3C. The aim of our study was to evaluate the predictive value of clinical response and survival of these new defined TS alleles. TS genotypes of 89 patients diagnosed with metastatic colorectal cancer and undergoing 5-FU-based chemotherapy were carried out. The clinical outcome was evaluated according to the genotype (high expression genotype: *2R/*3G; *3C/*3G; *3G/*3G; and low expression genotype: *2R/*2R; *2R/*3C; *3C/*3C. A higher overall response was observed in the group of patients with a low expression genotype (p = 0.035). The probability of achieving a clinical response of patients with a low expression-related genotype was 2.9 higher than that of the other group (95% CI = 1.03-5.6, p = 0.04). The median time to progression was 12 months and 9 months in the low and high expression groups, respectively (p = 0.07, log rank test). Overall survival was significantly longer in the low expression group. In this group the median OS was not achieved at 50 months of follow-up in contrast to the 20 months observed in the high expression group (p = 0.03). TS genotype was an independent predictor of progression-free and overall survival in the Cox regression models after adjustment to the other clinical variables. The selection of patients who are likely to respond to 5-FU therapy may be considerably improved if the TS genotype were to include both the VNTR and the SNP located within the promoter region of the gene. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15386371     DOI: 10.1002/ijc.20487

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.

Authors:  A Fariña-Sarasqueta; M J E M Gosens; E Moerland; I van Lijnschoten; V E P P Lemmens; G D Slooter; H J T Rutten; Adriaan J C van den Brule
Journal:  Cell Oncol (Dordr)       Date:  2011-06-01       Impact factor: 6.730

Review 2.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

3.  Modern origin of numerous alternatively spliced human introns from tandem arrays.

Authors:  Degen Zhuo; Richard Madden; Sherif Abou Elela; Benoit Chabot
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

4.  Genetic variants in the enhancer region of the thymidylate synthase gene in the Chilean population.

Authors:  M Acuña; L Eaton; L Cifuentes; D Massardo
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

5.  ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer.

Authors:  Ute Warnecke-Eberz; Daniel Vallböhmer; Hakan Alakus; Fabian Kütting; Georg Lurje; Elfriede Bollschweiler; Anke Wienand-Dorweiler; Uta Drebber; Arnulf H Hölscher; Ralf Metzger
Journal:  J Gastrointest Surg       Date:  2009-05-07       Impact factor: 3.452

6.  Polymorphisms of thymidylate synthase in the 5'- and 3'-untranslated regions and gastric cancer.

Authors:  Wen Zhuang; Xiao-Ting Wu; Yong Zhou; Guan-Jian Liu; Tai-Xiang Wu; Xun Yao; Liang Du; Mao-Ling Wei
Journal:  Dig Dis Sci       Date:  2008-11-07       Impact factor: 3.199

Review 7.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.

Authors:  Sudha Mannava; Vladimir Grachtchouk; Linda J Wheeler; Michael Im; Dazhong Zhuang; Elena G Slavina; Christopher K Mathews; Donna S Shewach; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2008-06-03       Impact factor: 4.534

9.  DMSO and betaine greatly improve amplification of GC-rich constructs in de novo synthesis.

Authors:  Michael A Jensen; Marilyn Fukushima; Ronald W Davis
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

10.  Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer.

Authors:  Peter P Grimminger; Jan Stöhlmacher; Daniel Vallböhmer; Paul M Schneider; Arnulf H Hölscher; Ralf Metzger; Peter V Danenberg; Jan Brabender
Journal:  J Oncol       Date:  2009-11-22       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.